Cognition Therapeutics Inc (NASDAQ:CGTX)’s traded shares stood at 1.78 million during the latest session, with the company’s beta value hitting 1.42. At the last check today, the stock’s price was $0.80, to imply an increase of 7.35% or $0.05 in intraday trading. The CGTX share’s 52-week high remains $2.95, putting it -268.75% down since that peak but still an impressive 32.5% since price per share fell to its 52-week low of $0.54. The company has a valuation of $32.30M, with an average of 0.58 million shares in intraday trading volume over the past 10 days and average of 947.21K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Cognition Therapeutics Inc (CGTX), translating to a mean rating of 1.57. Of 3 analyst(s) looking at the stock, 0 analyst(s) give CGTX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.21.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cognition Therapeutics Inc (NASDAQ:CGTX) trade information
After registering a 7.35% upside in the latest session, Cognition Therapeutics Inc (CGTX) has traded red over the past five days. The 5-day price performance for the stock is 25.37%, and -56.26% over 30 days. With these gigs, the year-to-date price performance is -56.49%. Short interest in Cognition Therapeutics Inc (NASDAQ:CGTX) saw shorts transact 1.77 million shares and set a 0.89 days time to cover.
Cognition Therapeutics Inc (CGTX) estimates and forecasts
Looking at statistics comparing Cognition Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Cognition Therapeutics Inc (CGTX) shares are -59.96% down over the last 6 months, with its year-to-date growth rate lower than industry average at -6.98% against 18.40%. Revenue is forecast to grow 4.50% this quarter before jumping 22.20% for the next one.
CGTX Dividends
Cognition Therapeutics Inc has its next earnings report out on 2024-Aug-08. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Cognition Therapeutics Inc (NASDAQ:CGTX)’s Major holders
Cognition Therapeutics Inc insiders hold 0.56% of total outstanding shares, with institutional holders owning 28.34% of the shares at 28.50% float percentage. In total, 28.34% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 1.15 million shares (or 3.4016% of shares), all amounting to roughly $1.9 million.
The next major institution holding the largest number of shares is AWM INVESTMENT COMPANY, INC. with 0.65 million shares, or about 1.9268% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $1.08 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Cognition Therapeutics Inc (CGTX) shares. Going by data provided on Mar 31, 2024 , Vanguard Total Stock Market Index Fund holds roughly 689.15 shares. This is just over 1.72% of the total shares, with a market valuation of $0.55 million. Data from the same date shows that the other fund manager holds a little less at 196.54, or 0.49% of the shares, all valued at about 0.16 million.
